
Stephen Lam Chan, MBBS, MD (CUHK), FRCP, discusses the lack of benefit with adjuvant pembrolizumab in HCC following a complete radiologic response.

Your AI-Trained Oncology Knowledge Connection!


Stephen Lam Chan, MBBS, MD, is a professor in the department of Clinical Oncology, The Chinese University of Hong Kong.

Stephen Lam Chan, MBBS, MD (CUHK), FRCP, discusses the lack of benefit with adjuvant pembrolizumab in HCC following a complete radiologic response.